cytokine platform collaboration with trutino biosciences
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine PlatformBoehringer Ingelheim will work with Trutino Biosciences to access the company ’s On-Demand-CytokineTM (ODC) platform to develop new cancer immunology compoundsThe partners aim to develop safer, more tolerable and more effective cytokine therapies for single agent and novel combinations with Boehringer Ingelheim ’s innovative cancer vaccine, oncolytic virus, T cell engager and myeloid-targeting therapies
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Research | Vaccines